# A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease

> **NCT05413655** · PHASE2 · RECRUITING · sponsor: **Excelsior** · enrollment: 120 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** EX039
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05413655
- **Lead sponsor:** Excelsior
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-02
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2025-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05413655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05413655, "A Study of Oral EX039 in Subjects with Mild Alzheimer's Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05413655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*